Warning Letter — Huons Co., Ltd.
The FDA issued a Warning Letter to Huons Co., Ltd. following an inspection by the Center for Drug Evaluation and Research (CDER). Details regarding the specific violations were not fully disclosed in the summary excerpt, but the issuance indicates significant deviations from current good manufacturing practice (CGMP).
This affects Huons Co., Ltd., its manufacturing leadership, quality assurance departments, and regulatory professionals responsible for ensuring the facility's compliance with FDA standards for drug production.
A Warning Letter from CDER typically signifies that a firm has failed to resolve observation findings from a prior inspection. This escalation suggests that the FDA may consider the firm's products to be adulterated, which could lead to import alerts, withholding of new drug approvals, or further enforcement actions if remediation is not successfully completed.
Quality and Manufacturing teams should conduct a gap analysis of current CGMP protocols against FDA requirements. Regulatory teams should prepare for potential import restrictions or the need for comprehensive remediation plans to address the issues cited in the Warning Letter.
FDA Warning Letter issued to: Huons Co., Ltd.. 06/15/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/huons-co-ltd-724650-06152026
Open in openFDA / FDA.gov